Literature DB >> 9024718

Diagnostic discrepancies and their clinical impact in a neuropathology referral practice.

J M Bruner1, L Inouye, G N Fuller, L A Langford.   

Abstract

BACKGROUND: During the course of their neuropathology practice, the authors received cases to review in consultation. In some cases, the patients came to the authors' hospital for therapy; in others, the primary pathologists requested a consultation. Because changes in diagnosis might significantly alter patient management, protocol entry, care costs, or the potential for physician liability, the authors determined the frequency and degrees of their disagreements with the original diagnoses submitted to them.
METHODS: The authors reviewed the first 500 brain or spinal cord biopsy cases that were submitted to their neuropathology consultation service for a second opinion in 1995. Disagreements were coded into 10 categories, but were grouped for this analysis as follows: serious (having immediate significance for therapy or intervention), less serious but potentially substantial (calling for a change in type or grade of glioma), minor (adding or deleting information), and those in which the authors made the first diagnosis themselves.
RESULTS: There was some degree of disagreement between the original and review diagnoses in 214 (42.8%) of the 500 cases. Disagreements were counted as serious in 44 cases (8.8%), less serious but substantial in 96 cases (19.2%), and minor in 50 cases (10.0%); the authors made the first diagnosis in 24 cases (4.8%).
CONCLUSIONS: Clinically important diagnostic errors that can affect immediate patient care decisions occur in a substantial number of brain and spinal cord biopsy cases. Thus, seeking expert neuropathology consultation is prudent and cost-effective for pathologists who are less experienced with these types of cases. Cost savings in case management might result from confirmation of diagnosis before definitive therapy is administered to the patients. The rates of discrepancy between original diagnoses and second opinions in other subspecialties of pathology should be examined.

Entities:  

Mesh:

Year:  1997        PMID: 9024718     DOI: 10.1002/(sici)1097-0142(19970215)79:4<796::aid-cncr17>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  The diagnostic "gold standard" in oncology: increasing importance and increasing concerns.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes.

Authors:  Rajiv Mangla; Daniel Thomas Ginat; Shervin Kamalian; Michael T Milano; David N Korones; Kevin A Walter; Sven Ekholm
Journal:  J Neurooncol       Date:  2013-11-01       Impact factor: 4.130

3.  Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 4.  Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification.

Authors:  Adriana Olar; Erik P Sulman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

5.  Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.

Authors:  Betty Y S Kim; Wen Jiang; Jason Beiko; Sujit S Prabhu; Franco DeMonte; Mark R Gilbert; Raymond Sawaya; Kenneth D Aldape; Daniel P Cahill; Ian E McCutcheon
Journal:  J Neurooncol       Date:  2014-04-29       Impact factor: 4.130

6.  The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium.

Authors:  E Susan Amirian; Georgina N Armstrong; Renke Zhou; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Faith G Davis; Rose Lai; Sanjay Shete; Christopher I Amos; Michael E Scheurer; Kenneth Aldape; Irina Alafuzoff; Thomas Brännström; Helle Broholm; Peter Collins; Caterina Giannini; Marc Rosenblum; Tarik Tihan; Beatrice S Melin; Melissa L Bondy
Journal:  Am J Epidemiol       Date:  2015-12-10       Impact factor: 4.897

Review 7.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

Authors:  Martin J van den Bent
Journal:  Acta Neuropathol       Date:  2010-07-20       Impact factor: 17.088

8.  Salivary type tumors seen in consultation.

Authors:  Simion I Chiosea; Robert Peel; E Leon Barnes; Raja R Seethala
Journal:  Virchows Arch       Date:  2009-03-07       Impact factor: 4.064

9.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

10.  Incidence of first primary central nervous system tumors in California, 2001-2005.

Authors:  Monica Brown; Rudolph Schrot; Katrina Bauer; Deanna Letendre
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.